Comparative Pharmacology
Head-to-head clinical analysis: ANJESO versus ARTHROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANJESO versus ARTHROTEC.
ANJESO vs ARTHROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Arthrotec is a combination of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and misoprostol, a synthetic prostaglandin E1 analog that protects the gastric mucosa by increasing mucus and bicarbonate secretion, enhancing mucosal blood flow, and promoting epithelial repair.
120 mg administered intravenously over 15 minutes, followed by 30 mg intravenously over 15 minutes, with the second dose given 12 to 24 hours after the first dose.
One tablet (diclofenac 50 mg / misoprostol 200 mcg) orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life is 1.5-2.5 hours in healthy adults. In elderly or renally impaired patients, half-life may extend to up to 6 hours.
Diclofenac: ~2 hours (range 1-4 h); misoprostol: 20-40 minutes (acid metabolite 1.5 h). No accumulation with repeated dosing.
Approximately 70% renal (30% unchanged, 40% as glucuronide conjugate), 30% fecal/biliary.
Renal: ~95% as metabolites (diclofenac: ~65% as glucuronide conjugates; misoprostol: ~80% as inactive metabolites). Biliary/fecal: <5%.
Category C
Category C
NSAID
NSAID